
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2020

Commission File Number: 001-38452

MEREO BIOPHARMA GROUP PLC

(Translation of registrant's name into English)

**4th Floor, One Cavendish Place,
London, W1G 0QE, United Kingdom**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Exhibit Index

Exhibits

99.1 [Regulatory News Service Announcement dated October 9, 2020.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 9, 2020

MEREO BIOPHARMA GROUP PLC

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel

**Mereo BioPharma Group plc
Director and PDMR Dealings**

London and Redwood City, Calif., October 9, 2020 – Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 7 2020 Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 12,711 American Depositary Shares (ADSs) at a price of USD 2.36 per ADS, Brian Schwartz, Non-Executive Director of Mereo, purchased 20,000 ADSs at a price of USD 2.35 per ADS and John Richard, Head of Corporate Development of Mereo, purchased 6,500 ADSs at a price of USD 2.36 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

1	Details of the person discharging managerial responsibilities					
a)	Name	Denise Scots-Knight				
2	Reason for the notification					
a)	Position/status	Chief Executive Officer				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Mereo BioPharma Group plc				
b)	LEI	213800U8JQHJOS5AS09				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument and identification code	MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)				
b)	Nature of the transaction	PURCHASE				
c)	Price(s) and volume(s)	<table border="1" style="width: 100%;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>USD 2.36</td> <td>12,711</td> </tr> </tbody> </table>	Price(s)	Volume(s)	USD 2.36	12,711
Price(s)	Volume(s)					
USD 2.36	12,711					
d)	Aggregated information: volume, Price	30043.72				
e)	Date of the transaction	2020-10-07				
f)	Place of the transaction	XNMS				

1	Details of the person discharging managerial responsibilities					
a)	Name	Brian Schwartz				
2	Reason for the notification					
a)	Position/status	Non-Executive Director				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Mereo BioPharma Group plc				
b)	LEI	213800U8JQHJOS5AS09				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument and identification code	MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)				
b)	Nature of the transaction	PURCHASE				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>USD 2.35</td> <td>20,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	USD 2.35	20,000
Price(s)	Volume(s)					
USD 2.35	20,000					
d)	Aggregated information: volume, Price	47068.00				
e)	Date of the transaction	2020-10-07				
f)	Place of the transaction	XNMS				

1	Details of the person discharging managerial responsibilities					
a)	Name	John Richard				
2	Reason for the notification					
a)	Position/status	Head of Corporate Development				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Mereo BioPharma Group plc				
b)	LEI	213800U8JQHJOS5AS09				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument and identification code	MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)				
b)	Nature of the transaction	PURCHASE				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>USD 2.36</td> <td>6,500</td> </tr> </tbody> </table>	Price(s)	Volume(s)	USD 2.36	6,500
Price(s)	Volume(s)					
USD 2.36	6,500					
d)	Aggregated information: volume, Price	15330.06				
e)	Date of the transaction	2020-10-07				
f)	Place of the transaction	XNMS				